What is Zacks Research’s Forecast for Revvity Q3 Earnings?

Revvity Inc. (NYSE:RVTY) – Analysts at Zacks Research upped their Q3 2026 earnings per share (EPS) estimates for shares of Revvity in a note issued to investors on Friday, September 4th. Zacks Research analyst Team now anticipates that the company will earn $1.28 per share for the quarter, up from their previous estimate of $1.27. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Revvity’s current full-year earnings is $5.37 per share. Zacks Research also issued estimates for Revvity’s Q4 2026 earnings at $1.65 EPS, Q3 2027 earnings at $1.45 EPS and Q2 2028 earnings at $1.66 EPS.

RVTY has been the subject of a number of other research reports. Wolfe Research initiated coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings raised Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Evercore reiterated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada began coverage on Revvity in a research note on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $114.77.

Revvity Stock Performance

NYSE:RVTY opened at $127.45 on Wednesday. The company has a market cap of $14.22 billion, a P/E ratio of 60.69, a P/E/G ratio of 2.37 and a beta of 1.09. Revvity has a twelve month low of $81.22 and a twelve month high of $133.00. The company’s 50-day moving average price is $117.12 and its 200-day moving average price is $102.75. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s payout ratio is currently 13.33%.

Hedge Funds Weigh In On Revvity

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its stake in shares of Revvity by 10,607.8% in the second quarter. California State Teachers Retirement System now owns 14,328,063 shares of the company’s stock valued at $1,594,140,000 after purchasing an additional 14,194,254 shares during the period. Jupiter Topco LLC purchased a new stake in Revvity during the 2nd quarter worth approximately $961,017,000. BlackRock Inc. acquired a new stake in Revvity during the 2nd quarter worth approximately $852,070,000. Wellington Management Group LLP lifted its holdings in Revvity by 10,653.8% during the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company’s stock worth $96,304,000 after buying an additional 857,526 shares in the last quarter. Finally, Primecap Management Co. CA acquired a new stake in Revvity during the 2nd quarter worth approximately $94,921,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.